Scleroderma, Systemic

"Scleroderma, Systemic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.

Descriptor ID	D012595
MeSH Number(s)	C17.300.799 C17.800.784
Concept/Terms	Scleroderma, Systemic Scleroderma, Systemic Systemic Sclerosis Sclerosis, Systemic Systemic Scleroderma

Below are MeSH descriptors whose meaning is more general than "Scleroderma, Systemic".

Diseases [C]
Skin and Connective Tissue Diseases [C17]
Connective Tissue Diseases [C17.300]
Scleroderma, Systemic [C17.300.799]
Skin Diseases [C17.800]
Scleroderma, Systemic [C17.800.784]

Below are MeSH descriptors whose meaning is related to "Scleroderma, Systemic".

Below are MeSH descriptors whose meaning is more specific than "Scleroderma, Systemic".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Scleroderma, Systemic" by people in this website by year, and whether "Scleroderma, Systemic" was a major or minor topic of these publications.

Bar chart showing 12 publications over 8 distinct years, with a maximum of 2 publications in 2002 and 2008 and 2010 and 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	0	2	2
2004	1	0	1
2008	2	0	2
2010	1	1	2
2016	0	2	2
2018	0	1	1
2021	1	0	1
2023	1	0	1

Below are the most recent publications written about "Scleroderma, Systemic" by people in Profiles.

?akan E, Ah Kioon MD, Garcia-Carmona Y, Glauzy S, Oliver D, Yamakawa N, Vega Loza A, Du Y, Schickel JN, Boeckers JM, Yang C, Baldo A, Ivashkiv LB, Young RM, Staudt LM, Moody KL, N?ndel K, Marshak-Rothstein A, van der Made CI, Hoischen A, Hayward A, Rossato M, Radstake TRDJ, Cunningham-Rundles C, Ryu C, Herzog EL, Barrat FJ, Meffre E. TLR9 ligand sequestration by chemokine CXCL4 negatively affects central B cell tolerance. J Exp Med. 2023 12 04; 220(12).

View in: PubMed
Wenzel D, Haddadi NS, Afshari K, Richmond JM, Rashighi M. Upcoming treatments for morphea. Immun Inflamm Dis. 2021 12; 9(4):1101-1145.

View in: PubMed
Birring SS, Kavanagh JE, Irwin RS, Keogh KA, Lim KG, Ryu JH. Treatment of Interstitial Lung Disease Associated Cough: CHEST Guideline and Expert Panel Report. Chest. 2018 10; 154(4):904-917.

View in: PubMed
Goyal A, Linskey KR, Kay J, Duncan LM, Nazarian RM. Differential Expression of Hedgehog and Snail in Cutaneous Fibrosing Disorders: Implications for Targeted Inhibition. Am J Clin Pathol. 2016 Dec; 146(6):709-717.

View in: PubMed
Mart?nez-Balzano CD, Touray S, Kopec S. Cystic Lung Disease Among Patients With Sj?gren Syndrome: Frequency, Natural History, and Associated Risk Factors. Chest. 2016 09; 150(3):631-9.

View in: PubMed
Kang J, Litmanovich D, Bankier AA, Boiselle PM, Eisenberg RL. Manifestations of systemic diseases on thoracic imaging. Curr Probl Diagn Radiol. 2010 Nov-Dec; 39(6):247-61.

View in: PubMed
Walkey AJ, Ieong M, Alikhan M, Farber HW. Cardiopulmonary exercise testing with right-heart catheterization in patients with systemic sclerosis. J Rheumatol. 2010 Sep; 37(9):1871-7.

View in: PubMed
Kay J. Nephrogenic systemic fibrosis: a new concern for rheumatologists. Nat Clin Pract Rheumatol. 2008 Sep; 4(9):445.

View in: PubMed
Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008 Aug; 58(8):2543-8.

View in: PubMed
Chen Y, Leask A, Abraham DJ, Pala D, Shiwen X, Khan K, Liu S, Carter DE, Wilcox-Adelman S, Goetinck P, Denton CP, Black CM, Pitsillides AA, Sarraf CE, Eastwood M. Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts. Arthritis Rheum. 2008 Feb; 58(2):577-85.

View in: PubMed

People

Explore

Similar Concepts

Top Journals